Pharma and healthcare: sector news on Thursday 5 November 2026
Average tone −0.1 (neutral) across 5 companies with relevant coverage, from 63 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +6.3 | 24 | Most coverage concerned reports that AstraZeneca offered $10 billion to buy Rhythm, a maker of obesity drugs, which was viewed as a strategic expansion. |
| Smith & Nephew | −8.3 | 19 | Coverage focused on Smith & Nephew lowering its 2026 guidance because of weak US orthopaedics and wound care sales, alongside the end of talks with Johnson & Johnson's orthopaedics unit. |
| GSK | +5.0 | 11 | Most coverage was about HP naming GSK's former chief as its CEO, which says little about GSK itself. |
| Haleon | −6.7 | 8 | Coverage was dominated by Jefferies cutting its rating on Haleon over margin worries and weaker sales outside oral care, alongside a share price slide after a trimmed growth outlook. |
| Convatec | +3.0 | 1 | Coverage focused on Convatec appointing a new chief financial officer, which brought the company back to investors' attention. |
Strongest stories in the sector
- +10.0 Canadian approval of a first-of-kind hepatitis B therapy.
- −10.0 Lower guidance driven by declining US hip and knee demand.
- −10.0 Lower annual guidance because of US orthopaedics weakness.
- −10.0 Annual guidance lowered as US orthopaedics demand weakens.
- −10.0 Broker expects shares to drop after lowered guidance and weak wound care.
- −10.0 Quarterly revenue below forecasts and weaker outlook on US market.
- +9.2 Earnings ahead of expectations and guidance reaffirmed.
- −9.2 Analyst flags profitability reset and sluggish sales outside one category.
- −9.2 Share price falling on the day after the update.
- −9.2 Share price falling on the day after the update.
- +8.3 Strong quarterly growth supports unchanged full-year expectations.
- +8.3 Robust quarter and unchanged guidance.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.